|

The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study

RECRUITINGSponsored by Centro di Riferimento Oncologico - Aviano
Actively Recruiting
SponsorCentro di Riferimento Oncologico - Aviano
Started2023-05-22
Est. completion2032-12-31
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT06136949

Summary

This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
* Age ≥18 years.
* Signed informed consent form.
* Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.

Exclusion Criteria:

* Patients for which the tumour biobanking process could compromise the diagnostic assessments.
* Pregnancy or breast-feeding.
* History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.

Conditions2

CancerColorectal Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.